Coming Soon
Find comprehensive information on mole diagnosis, including atypical mole, dysplastic nevus, melanoma, and benign nevus. This resource covers clinical documentation, ICD-10 codes (D22), SNOMED CT codes, and dermoscopic features for accurate mole evaluation and medical coding. Learn about biopsy procedures, histopathology, and differential diagnosis for proper mole identification and management in healthcare settings.
Also known as
Melanocytic nevi
Benign melanocytic tumors of the skin.
Congenital melanocytic nevus
A mole present at birth.
Atypical melanocytic nevus
Moles with unusual features, sometimes precancerous.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the mole congenital?
When to use each related code
| Description |
|---|
| Common mole (nevus) |
| Atypical mole (dysplastic nevus) |
| Actinic keratosis |
Incorrect coding of benign (e.g., D22) vs. malignant (e.g., C44) moles impacts reimbursement and quality reporting.
Lack of precise site documentation can lead to inaccurate coding and affect skin cancer tracking.
Dysplastic nevi (D22.1) require specific documentation to support the diagnosis and avoid downcoding.
Q: What are the key dermoscopic features that differentiate a benign melanocytic nevus from melanoma in adult patients?
A: Differentiating benign nevi from melanoma relies on careful dermoscopic evaluation. Benign features include symmetry, regular borders, homogenous color, and a well-defined structure (e.g., globular, reticular). Melanoma, however, often presents with asymmetry, irregular borders, color variegation (e.g., blue-white veil, irregular dots/globules), and chaotic structures (e.g., atypical pigment network). Specific dermoscopic criteria like the ABCD rule, the 7-point checklist, and the Menzies method can aid in this differentiation but should be used in conjunction with clinical context, patient history, and potentially, additional investigations like total body photography or sequential digital dermoscopy imaging. Explore how these dermoscopic criteria can be integrated into your practice for more confident mole assessment.
Q: When should a shave biopsy vs. an excisional biopsy be preferred for mole removal and histopathological evaluation considering current best practice guidelines?
A: The choice between shave and excisional biopsy depends primarily on clinical suspicion for melanoma. Excisional biopsy with narrow margins is the preferred method for suspicious lesions as it allows for complete removal and accurate histopathological assessment including Breslow thickness if melanoma is confirmed. Shave biopsy might be acceptable for clearly benign lesions with a low risk of melanoma where cosmesis is paramount, but carries a risk of sampling error, incomplete removal, and difficulty in accurately staging melanoma if present. When considering a shave biopsy, ensure the lesion base is completely removed. Consider implementing a comprehensive patient discussion regarding the benefits and limitations of each approach, emphasizing the importance of complete excision for suspected melanoma. Learn more about current best practice guidelines from professional organizations like the American Academy of Dermatology and the National Comprehensive Cancer Network.
Patient presents with a pigmented skin lesion concerning for a mole, also known as a nevus. The lesion was evaluated for asymmetry, border irregularity, color variation, diameter, and evolving features (ABCDEs of melanoma). Location, size, shape, color, surface texture, and any associated symptoms such as itching, bleeding, or pain were documented. Differential diagnoses considered include atypical nevus, dysplastic nevus, melanoma, seborrheic keratosis, and lentigo. Dermoscopic examination was performed to assess for specific dermoscopic features such as pigment network, globules, streaks, and blue-white veil. Photographs were taken for documentation and future comparison. Based on the clinical and dermoscopic findings, the lesion is consistent with a benign melanocytic nevus. Patient education was provided regarding sun protection, skin self-exams, and signs of concerning changes in moles. No immediate intervention is required at this time. Follow-up is recommended for any changes in size, shape, color, or symptoms. ICD-10 code D22.6 (benign neoplasm of skin of other and unspecified parts of face) or other appropriate ICD-10 code based on location was considered. CPT codes for evaluation and management (99202-99215) or dermoscopy (96921-96923) may be applicable depending on the complexity of the visit.